CTLA4 and melanoma: Recent advancements in immunotherapy for melanoma include the blockade of immune checkpoint proteins (ICPs), Programmed Death-1 (PD-1), Programmed Death-Ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4).